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Pulmonary artery hypertension is characterized by proliferation in the resistance vessels. A recent study in
Science Translational Medicine (Sutendra et al., 2010) found that increased fatty acid oxidation and a shift
in the glycolysis/glucose oxidation ratio may be central to the pathogenesis of this process, suggesting
that these abnormalities comprise novel treatment targets.Pulmonary hypertension, characterized
by a mean pulmonary artery pressure
>25 mmHg, is a hemodynamic abnor-
mality shared by a variety of cardiac
and pulmonary diseases, including left
ventricular dysfunction and valvular dis-
ease, chronic obstructive and restrictive
lung diseases, and chronic thromboem-
bolic disease. The term pulmonary artery
hypertension (PAH) refers to conditions
in which intrinsic abnormalities of the
resistance pulmonary arteries lead to pro-
gressive vascular proliferation and exten-
sive remodeling, ultimately leading to
severely elevated pulmonary vascular re-
sistance, right ventricular failure, and
death (Chin and Rubin, 2008). PAH is an
increasingly frequent cause of death in
systemic sclerosis, HIV infection, and
congenital heart disease. When PAH
occurs in the absence of underlying eti-
ology, it is called idiopathic PAH (IPAH),
a rare condition with an annual incidence
of 1–2 per million. A familial form of PAH
exists that accounts for approximately
20% of cases of ‘‘idiopathic’’ PAH. A
number of genetic abnormalities have
been identified in this population, notably
mutation in the bone morphogenetic
protein receptor 2 (BMPR2), a member
of the TGF-b superfamily (Morrell, 2010).
The pathogenesis of PAH remains
poorly understood. Although a variety of
functional abnormalities have been identi-
fied, particularly in IPAH, it is unclear
whether the process is initiated in the
endothelial or smooth muscle cells (Yuan
and Rubin, 2005). Nevertheless, the dem-
onstration of endothelial cell dysfunction,
including enhanced endothelin synthesis
and impaired production of prostacyclin
and nitric oxide, has led to the develop-
ment of targeted therapies, includingendothelin receptor antagonists, prosta-
cyclin analogs, and drugs that augment
nitric oxide-mediated local effects such
asphosphodiesterase type5 (PDE5) inhib-
itors (Chin and Rubin, 2008). While these
therapies have improved outcomes for
patients with PAH, they are not universally
effective, nor are they curative, underscor-
ing the need for additional therapies that
target upstream pathogenic processes.
It has been known for nearly 70 years
thathypoxia results inpulmonaryvasocon-
striction. In the setting of chronic hypoxia,
i.e., in patients with chronic lung disease,
this vasoconstriction progresses to vascu-
lar remodeling and contributes to chronic
pulmonary hypertension. Hypoxic vaso-
constriction is unique and intrinsic to
pulmonary vascular smooth muscle cells
and is due to hypoxia-induced inhibition
of the voltage-gatedKv1.5 channel, leading
to cell membrane depolarization and an
influx of calcium into the cytoplasm (Yuan
et al., 1993). However, the intracellular
linkbetweenacuteconstrictionandsubse-
quent cellular proliferation has not been
elucidated. The smooth muscle cell as
the site of disease initiation in IPAH has
also been a source of interest since the
suggestion by the eminentBritishcardiolo-
gist Paul Wood over 50 years ago that this
disease was associated with a ‘‘vasocon-
strictive factor.’’ Dysfunctional Kv1.5 chan-
nels and increased intracellular calcium
levels have also been demonstrated in
pulmonary artery smooth muscle cells
from patients with IPAH, lending support
to the notion that intrinsic abnormalities in
these cells are also important in the patho-
genesis of this disease (Yuan et al., 1998;
Remillard et al., 2007; Yu et al., 2004).
A unique feature of PAH cells is their
resistance to apoptosis (Krick et al.,Cell Metabolism 12001). This finding, coupled with others
that are shared by malignant cells, has
led to the ‘‘cancer hypothesis’’ in PAH,
i.e., that the growth and proliferation of
the pulmonary vasculature is akin to that
observed in malignancies (Rai et al.,
2008). Despite encouraging results in
PAH animal models using anticancer
drugs such as the tyrosine kinase inhibitor
Imatinib, early clinical trials in PAH have
been mixed, in part due to the systemic
toxicities of these agents.
In a recent study, Sutendra et al. (2010)
hypothesized that PAH may share meta-
bolic abnormalities with cancer that
account for the resistance to apoptosis.
Specifically, the authors hypothesized that
an increase in the rate of glycolysis and
impaired glucose oxidation leads to resis-
tance to apoptosis in PAH. In a series of
extensive and elegant experiments using
animalmodelsof acute andchronic pulmo-
nary hypertension, they found that mice
deficient in malonyl-CoA decarboxylase
(MCD), a key regulatory enzyme for fatty
acid oxidation that helps control the ratio
of glucose oxidation and glycolysis,
demonstrated attenuated vasoconstriction
and vascular remodeling. Additionally, they
demonstrated that treatment with meta-
bolic modulators dichloroacetate and tri-
metazidine, which mimic MCD deletion
and decrease the ratio of glycolysis/
glucose oxidation, reversed the hemody-
namic and vascular proliferation in chroni-
cally hypoxic mice and rats with monocro-
taline-induced pulmonary hypertension.
Linking theseobservationswith ionchannel
function, they showed that MCD-deficient
mice manifested attenuated inhibition of
Kv channel activity and decreased cyto-
solic calcium with hypoxia; furthermore,
metabolic inhibitors reduced the elevated2, October 6, 2010 ª2010 Elsevier Inc. 313
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Previewsintracellular calcium levels in cells from
a patient with IPAH obtained at the time of
lung transplantation. Taken together, these
findings provide a link between an intrinsic
metabolic abnormality of pulmonary
vascular cellular mitochondria, affecting
acute vasoconstriction and resistance to
apoptosis, and vascular remodeling.
While the studies by Sutendra et al.
provide important connections between
a variety of independent observations
and lead to a plausible mechanism of
upstream pathogenesis of PAH, there
are a number of unanswered questions:
1. The degree of vasculopathy seen in
chronic hypoxia is quite modest
compared to that observed in PAH,
and the former is generally reversible
upon restoration of normoxic condi-
tions, while the latter is, at least for
now, irreversible. Accordingly, the
extrapolation from hypoxic pulmo-
naryhypertension toPAH is tenuous.
2. The translation of findings in animal
models of PAH, particularly mono-
crotaline-induced PAH, to the clin-
ical arena has been disappointing,
with a number of drugs or other
interventions demonstrating dra-
matic results in animals and either
no effect or, at best, a modest
effect in patients.
3. The role of the endothelial cell in the
pathogenesis of PAH remains314 Cell Metabolism 12, October 6, 2010 ª20unclear, and these experiments
did not include studies of these
cells. Thus, it remains unclear
whether endothelial dysfunction is
an early or late event in the patho-
genesis of PAH or whether an
endothelial-smooth muscle inter-
action early in the disease process
is important.
4. The impact on proliferation of
human cells exposed to the meta-
bolic inhibitors was not investi-
gated, an observation that would
have provided a much stronger
link between altering intracellular
calcium and remodeling.
5. The authors examined cells from a
single patient with ‘‘IPAH.’’ Whether
their observations will be reinforced
with experiments from cells ob-
tained from other patients with this
or other forms of PAH is unclear.
Despite these limitations, Sutendra
et al. have advanced our understanding
of the pathogenesis of pulmonary vas-
cular disease and have pointed us in the
direction of a new and selective target
for therapy. While more work needs to
be done before a formal clinical trial
of metabolic inhibitors should be enter-
tained, the prospect of reversing the
vasculopathy of PAH is exciting and
brings a new set of colleagues—experts
in metabolism—into the battle.10 Elsevier Inc.REFERENCES
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Replacement of nonvascular cartilage by bone and bone marrow is a critical step in bone development. In
a recent issue of Developmental Cell, Maes et al. (2010) report that a distinct population of immature precur-
sors of bone-forming cells migrate into the cartilage in intimate association with invading blood vessels.The development of most bones, such as
bones in the limbs and spine, proceeds
via a two-stage process known as endo-
chondral ossification. The architecturalmodeling of a bone takes place in the
location of the future bone via assembly
of a template. The template consists of
hyaline cartilage, a nonvascular tissuecomposed of chondrocytes dispersed
within a complex extracellular matrix. As
the template grows and takes on the
shape of the future bone, chondrocytes
